



Krajská nemocnice Liberec, a.s.
nemocnice Liberec nemocnice Turnov

Optimalizace CRT v roce 2018

Rostislav Polášek

Kardiologické oddělení

Krajská nemocnice Liberec a.s.

1. Před implantací

- selekční kritéria

2. Při implantaci

- poloha elektrod

3. Po implantaci

- Individualizace AVD, VVD
- Maximalizace %VP
- Farmakoterapie





LBBB

X


RBBB

RV

LV



1. selekční kritéria CRT – non LBBB?



1. selekční kritéria CRT – non LBBB?

Morbidita a mortalita v RCT

Table 5 Hazard ratios for CRT-D vs ICD for occurrence of the primary endpoint (first hospitalization for heart failure or death) in the MADIT-CRT study by QRS morphology

QRS category	Hazard ratio (n)	P value
LBBB	0.45 (1281)	<.05
RBBB	0.96 (228)	NS
IVCD/other	1.42 (309)	NS

CRT = cardiac resynchronization therapy; ICD = implantable cardioverter defibrillator; IVCD = nonspecific interventricular conduction defect; LBBB = left bundle branch block; RBBB = right bundle branch block.

Modified from Zareba et al.¹⁷

Cardiac resynchronization therapy implantation in patients with heart failure (1)

Recommendations	Class	Level
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	A
CRT should be considered for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and non-LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	IIa	B
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	B
CRT may be considered for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and non-LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	IIb	B

Poznámky z praxe

- Neléčíme CRT non LBBB pacienty pokud nejsou indikováni k ICD, pacienty s QRSd > 150 individuálně zvažujeme
- Při indikaci k ICD zvažujeme CRT i non LBBB (pravděpodobný upgrade)
- Zvažujeme aktivaci/deaktivaci biv. stimulace podle klinické odpovědi




Jak optimalizovat polohu LV elektrody

- Anatomicky – non apical
- Elektricky
- Echokardiograficky




2. poloha elektrod

Elektrická poloha LV elektrody: QLV




2. poloha elektrod




n = 161


QLV (ms) by tertiles



Q-LV ratio: Heart failure morbidity and mortality




ECHO poloha LVel – TARGET trial




TARGET

Combined Endpoint of Death and Heart Failure Related Hospitalisation between the TARGET and Control Groups



No. At Risk	0	200	400	600
TARGET	110	102	59	18
CONTROL	110	101	61	17

Combined Endpoint of Death and Heart Failure Related Hospitalization According to LV Lead Position




No. At Risk	0	200	400	600
Concordant	124	109	69	21
Adjacent	58	46	31	12
Remote	29	25	13	5

Figure 4 Kaplan-Meier Curves Comparing Both Randomized Groups

Figure 5 Kaplan-Meier Curves Comparing Groups According to LV Lead Position


2. poloha elektrod

Aktivace LV u LBBB/IVCD je variabilní – epikardiální aktivační mapy




Porovnání polohy chirurgicky zavedené LVEI navigované vs empirické


Group A EP navigated



Group B Empiric



Toto není laterální poloha LVel.



Poznámky z praxe

- LVel. – cílem je $QLVratio > 0,70$
 - Hledáme jinou větev
 - Zvažujeme chirurgickou implantaci (navigovanou)
- Poloha RV elektrody
 - RCT negativní
 - volíme septální pozici



- Titrace blokátorů RAAS
 - ACE-I
 - MRA
 - BB
- Diuretika – úprava podle symptomů
 - Snížení FSM
 - Záměna FSM za Hydrochlorothiazid?
- U dále symptomatických ARNI




3. Po implantaci – maximalizace BivP paced

- Nedostatečný podíl BivP
 - AF
 - VPC
- Podhodnocení čítači přístroje – (trigger modes)
- Role dálkové monitorace
- Časná RFA AV junkce u FS a “incomplete BivP”




maximalizace BivP paced

Study name



3. Po implantaci – dálková monitorace




3. Optimalizace po implantaci

Co dále?

Stačí rutinní nastavení? AVD 100-120ms, VVD 0ms



HF morbidity/mortality podle reversní remodelace LK v 1 roce



3. Optimalizace po implantaci

Co dále?

Stačí rutinní nastavení AVD 100-120ms, VVD 0ms

Rozhodnutí podle ECHO odpovědi


Individualizace AVD, VVD

Automatické algoritmy pro AVD, VVD


MPP, AdaptiveCRT



3. Po implantaci – individuální AVD



3. Po implantaci – VV optimisation



3. Po implantaci – electrogram based AVD optimisation


- QuickOpt (St Jude Medical)
- AdaptivCRT (MEDTRONIC)
- EEHF + (BOSTON SCIENTIFIC)

- Výsledky těchto algoritmů vzájemně nekorelují
- Nekorelují s hemodynamickou optimalizací

- Nedoporučujeme provádět rutinně!!


ADaptivCRT™

Algorithm Operation



Adaptivcrt™ improves patient outcomes by...


Reducing a patient's odds of a 30-Day HF Readmission* by 59%¹
For all patients



* Readmissions following an HF hospitalization.

¹ Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572.

MultiPoint™ Pacing (MPP)




MultiPoint™ Pacing Improves Mechanical Dyssynchrony

Methods:

- Acute pacing protocol consisting of BiV simultaneous pacing and a set of 8 MultiPoint Pacing interventions covering a range of LVLV and LVRV delay combinations.

Results:

- In 67% of patients, at least one MultiPoint Pacing intervention exhibited a significant reduction ($\geq 20\%$) in dyssync



- K optimálnímu výsledku CRT je nezbytná
 - Správná indikace – LBBB, RVS
 - Optimální poloha LVel
 - OMT
 - Max. %BivP



Závěr

- Ostatní metody optimalizace – individualizovaný AVD, VVD, MPP, AdaptiveCRT mají své místo u nemocných, u kterých nedojde ke strukturální odpovědi na CRT, jejich účinnost je ale omezená
- Nedořešenou otázkou je reimplantace LVel. u její suboptimální polohy





Děkuji za pozornost

